Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT04465838
Recruiting Observational

Chinese Psoriasis Real World Evidence Research

NCT04465838 · tracked via the Priya Life Science China tracker
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Observational
Started
2020-07-08
Last updated
2024-01-05

Condition(s) studied

Psoriasis

Investigational drug(s) / intervention(s)

NIS

NIS: This is a non-interventional study (NIS).

Study summary

This research is a multicenter,observational study under real world settings in patients diagnosed as psoriasis by dermatologist in the clinic. As patient's choice of medication should be fully respected, all the patients can choose the treatments they prefer, like phototherapy, traditional systemic therapy or biologics. And the study was conducted to compare the effectiveness among different choices of medication in Chinese psoriasis patients.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * all the patients diagnosed as psoriasis by dermatologist in clinic. Exclusion Criteria: * None

Primary outcome measure(s)

  • The percentage of patients who achieved a PASI reduction of 100% (PASI 100) — 6 months
    Psoriasis Area and Severity Index includes scores of erythema, infiltration and desquamation, weighted by area of involvement in each regions (head and neck, upper extremities, trunk, lower extremities), with higher PASI scores indicating worse condition. The percentage of patients who achieved a PASI reduction of 100% (PASI 100) will be measured.

Trial sites (29)

FacilityCityRegionStatus
Second Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou Zhejiang Recruiting
Beijing Children's Hospital Affiliated to Capital Medical University Beijing China Recruiting
the First Affiliated Hospital of Chongqing Medical University Chongqing China Recruiting
the First Affiliated Hospital of Fujian Medical University Fujian China Recruiting
General Hospital of Lanzhou Military Region Gansu China Recruiting
Sun Yat-sen Memorial Hospital Guangdong China Recruiting
The Peoples' Hospital of Guangxi Zhuang Autonomous Region Guangxi China Recruiting
the Affiliated Hospital of Guizhou Medical University Guizhou China Recruiting
The Fifth People's Hospital of Hainan Province Hainan China Recruiting
the First Hospital of Hebei Medical University Hebei China Recruiting
the Second Affiliated Hospital of Harbin Medical Unviersity Heilongjiang China Recruiting
Henan Provincial Peoples' Hospital Henan China Recruiting
the Affiliated Hospital of Inner Mongolia Medical University Hohhot China Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Hubei China Recruiting
Xiangya Hospital, Central South University Hunan China Recruiting
the Second Affiliated Hospital of Nanchang University Jiangxi China Recruiting
Yanbian University Hospital Jilin City China Recruiting
Institute of Dermatology, Chinese Academy of Medical Sciences Nanjing China Recruiting
Xining First Hospital Qinghai China Recruiting
Shandong Provincial Hospital for Skin Diseases Shandong China Recruiting
Shanghai Dermatology Hospital Shanghai China Recruiting
Taiyuan Central Hospital Shanxi China Enrolling By Invitation
the Second Affiliated Hospital of Xi'an Jiaotong University Shanxi China Recruiting
the First hospital of China Medical University Shenyang China Recruiting
Sichuan Provincial People's Hospital Sichuan China Recruiting
Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital Tianjin China Recruiting
First Affiliated Hospital, School of Medicine, Shihezi University Xinjiang China Recruiting
General Hospital of Ningxia Medical University Yinchuan China Recruiting
the Second Affiliated Hospital of Kunming Medical University Yunnan China Recruiting

More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China

Laparoscopic Versus Open Surgery for Colon Cancer With Visceral Obesity Recruiting
Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence Starting soon
Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL Recruiting
A Study on Predicting the Risk of Distant Metastasis in Breast Cancer Using AI-Generated Spatial Pathological Maps Recruiting
Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer Recruiting

Other trials for the same condition

Trial of HSK44459 Cream for the Management Plaque Psoriasis Active, not recruiting
Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial Recruiting
A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis Starting soon
A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis Starting soon
A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04465838 on ClinicalTrials.gov ↗ ← All trials in China